Sleep disorders in end-stage renal disease: ‘Markers of inadequate dialysis?’  by Perl, J. et al.
Sleep disorders in end-stage renal disease: ‘Markers
of inadequate dialysis?’
J Perl1, ML Unruh2 and CT Chan1
1Division of Nephrology, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada and 2Renal-Electrolyte Division,
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Excessive daytime sleepiness and sleep disorders, including
sleep apnea syndrome, restless legs syndrome, and periodic
limb movement disorder, occur with increased frequency in
patients with end-stage renal disease (ESRD). The detection
and management of sleep disorders in ESRD patients is often
challenging but may have significant clinical benefits. Some
of the poor quality of life in ESRD may be attributed to the
presence of concomitant sleep disorders, yet the classical
symptoms of sleep disorders (poor concentration, daytime
sleepiness, and insomnia) are often ascribed to the uremic
syndrome itself. Conventional risk factors and screening tools
used in the diagnosis of sleep disorders seem to have limited
applicability in dialysis patients implicating the unique
pathophysiology of sleep disorders in ESRD. Emerging
evidence suggests that sleep apnea may contribute to the
augmented cardiovascular event rates and to the accelerated
development of atherosclerosis in ESRD. Whether treatment
of sleep disorders in ESRD patients can affect the high
morbidity and mortality of ESRD patients has yet to be
elucidated. To date, conventional renal replacement
therapies do not appear to have a significant impact on the
treatment of sleep disorders in ESRD. The promising
therapeutic effects of optimal uremia control in the forms of
nocturnal hemodialysis and renal transplantation on sleep
disorders require further mechanistic and clinical studies.
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The purpose of the present review is to examine the
interactions between end-stage renal disease (ESRD) and
sleep disorders. We will summarize the present knowledge on
the epidemiology, pathogenesis, clinical sequelae, and treat-
ment options for these specific uremia-associated sleep
disorders. We speculate that uremia is critical in the
development of sleep disorders in ESRD and that manipula-
tion of uremia control represents a promising therapeutic
approach.
DAYTIME SLEEPINESS IS PREVALENT IN UREMIA ASSOCIATED
SLEEP DISORDERS
Sleep complaints are highly prevalent in ESRD patients with
sleep disorders. Subjective assessments using standardized
questionnaires have demonstrated a prevalence of daytime
sleepiness in 52–67% of patients with ESRD.1,2 Intriguingly,
in addition to the high rate of excessive daytime sleepiness
(EDS), up to 50% of ESRD patients complained of
concomitant insomnia compared to 12% in control subjects.3
Diagnosis of daytime sleepiness may be made by self-
report questionnaires. Although standardized questionnaires
have been used widely in the non-ESRD population, these
instruments have not been well validated in ESRD patients.
In a study by Unruh et al.,4 two commonly used sleep
questionnaires: the Epworth Sleepiness Scale and the Sleep
Problems Index were administered to control subjects and
ESRD patients. The Epworth Sleepiness Scale provides a
measure of daytime sleepiness and the Sleep Problems Index
aims to assess sleep quality. Although the Epworth Sleepiness
Scale scores were not significantly different between the two
groups, the Sleep Problems Index scores demonstrated
impaired subjective sleep quality in ESRD patients compared
to control subjects. These results highlight the complexity of
sleep complaints in the ESRD population and illustrate some
of the limitations of subjective testing in detecting the
presence of poor sleep quality and a potential underlying
sleep disorder. Comprehensive screening for sleep disorders
and complaints in the ESRD population should therefore
require the use of validated objective testing.
Multiple sleep latency test (MSLT) is an objective,
validated measure of daytime sleepiness.5–7 MSLT is typically
performed following a sleep study, where a patient is asked to
take five naps throughout the day. Sleep latency is defined as
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the time from ‘lights out’ to the onset of sleep. A sleep latency
of less than 5 min is considered to be ‘pathological’
sleepiness.7,8
Three studies have reported on the results of MSLT among
ESRD patients.1,9,10 Although all studies document a high
prevalence of abnormal MSLT in ESRD patients, some
disparity exists in the severity and associated risk factors of
daytime sleepiness. Stepanski et al.1 evaluated 18 peritoneal
dialysis patients with sleep complaints. As a whole, the
cohort’s MSLT was 6.673.7 min. Of interest, patients with
co-existing sleep apnea were found to have lower MSLT of
5.574 min. In another study, 24 consecutive ESRD patients
were studied.9 The MSLT was abnormal in 50% of patients
and was directly associated with plasma urea concentrations
and the frequency of periodic limb movements but not to the
presence of apnea. In comparison, Parker et al.10 studied 46
ESRD patients and found that 13% had abnormal MSLT
whereas 33% had mildly abnormal MSLT (5–10 min).
Intriguingly, these investigators also reported that 48% of
the studied population had at least one sleep-onset rapid eye
movement sleep during the five MSLT nap opportunities. In
addition, the number of sleep-onset rapid eye movements
was negatively related to MSLT scores.10 It is important to
note that this study excluded those ESRD patients thought to
have sleep disorders and therefore the somewhat divergent
findings may reflect the different populations. In contrast to
previous study, MSLT did not correlate with the degree of
apnea.
One explanation for the EDS in ESRD is the notion of
day/night sleep reversal, which has often been cited as a
cardinal feature of uremia.11–14 Multiple hypotheses have
been proposed to account for uremia-induced daytime
sleepiness including (1) subclinical uremic encephalopathy,15
(2) abnormal metabolism and retention of melatonin,16
(3) tyrosine deficiency leading to diminished neurotransmit-
ters associated with arousal,17 (4) alteration in body
temperature rhythm resulting in a perturbation of the
sleep-wakefulness cycle,18 (5) release of sleep-inducing
inflammatory cytokines during dialysis,19,20 (6) the effects
of dialysate temperature on sleep,18 and (7) co-existent sleep
apnea syndrome (SAS).11
EDS and sleep complaints are common in ESRD patients
with or without sleep disorders.4 The pathogenesis of daytime
sleepiness is likely multifactorial and may be common to a
number of the uremia-associated sleep disorders.14 At present,
multiple proposed mechanisms have been hypothesized for
the development of EDS. Moreover, daytime sleepiness may
contribute to the poor vocational and rehabilitation potential
traditionally associated with ESRD.21 A mechanistic analysis
of the biology underlying the development of day/night
reversal and EDS will likely enhance our understanding of
uremia-associated sleep disorders.
SLEEP DISORDERED BREATHING IN ESRD
The SAS is characterized by repetitive cessation of respiration
during sleep resulting in oxygen desaturation and arousal.
A definitive diagnosis is made by overnight polysomnography
(PSG). However, because of significant night to night
variability, a repeat PSG may be required in the setting of
one normal study if a high index of suspicion is present.22 An
apnea is defined as the absence of airflow for 10 s or greater. If
apnea is accompanied by evidence of continued respiratory
effort, it is defined as obstructive apnea. In contrast, if there is
no evidence of respiratory effort during apnea, it is termed
central apnea. Apneas may also be classified as mixed if
respiratory effort is present, but delayed. A hypopneic
episode occurs when airflow decreases by 50% for 10 s or
decreases by 30% if there is an associated decrease in the
oxygen saturation or an arousal from sleep.23 The apnea–-
hypopnea index (AHI) is determined by the total number of
apneas and hypopneas during sleep divided by the total
number of hours of sleep. An AHI of 5–15 is considered mild
apnea. An AHI of 15–30 is usually categorized as moderate
apnea. An AHI of greater than 30 is classified as severe apnea.
Another commonly used parameter is the respiratory
disturbance index. The respiratory disturbance index also
includes those respiratory events which result in arousal and
is also used in certain diagnostic criteria.24
PREVALENCE AND CLINICAL FEATURES OF SLEEP APNEA
IN ESRD
The prevalence of SAS in the middle-aged, general popula-
tion has been reported to be 2–4%.25 In contrast, studies in
the dialysis population using survey questionnaires and
overnight PSG have demonstrated a prevalence rate of greater
than 50%.1,26–29 Co-morbid conditions such as cardio-
vascular disease, diabetes mellitus, and obesity coupled with
selection bias in these studies may explain in part the high
prevalence of SAS in ESRD.
In comparison to the non-ESRD population, several
clinical features are thought to be unique to the SAS in
ESRD. In the general population, obstructive sleep apnea is
the predominant phenotype. In contrast, SAS seen in ESRD
patients has been characterized by varying degrees of
obstructive, mixed, and central sleep apnea.30–32 Also in
contrast to the general population, higher body mass index
and male sex are not consistently associated with SAS in
ESRD patients.1,28,33,34 The lack of association between SAS
and usual risk factors may in part reflect the limitations of
previous studies of ESRD patients. Previous studies have been
small and may suffer from a lack of power to detect an
association of SAS with conventional risk factors. In addition,
the classical symptoms of sleep apnea such as snoring are less
commonly encountered in apneic ESRD patients.33,34 Taken
together, the clinical presentation of SAS in ESRD presents a
difficult diagnostic and therapeutic challenge.
PATHOPHYSIOLOGY OF SLEEP APNEA IN UREMIA
Although the pathogenesis of SAS in ESRD requires further
elucidation, several uremic risk factors have been proposed.
From a simplistic viewpoint, uremia may exacerbate sleep
apnea in ESRD by accumulation of uremic toxins, by volume
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overload, or both. Suggestion that the accumulation
of ‘toxic products’ and the altered biochemical milieu may
contribute to uremia-related sleep disorders stems from
the observation that infusion with branched chain amino
acids has been associated with (1) a return of rapid
eye movement (REM) sleep to normal and (2) a significant
decrease in end-tidal carbon dioxide during both REM and
non-REM sleep.35 It is particularly interesting to note that
respiratory stimulation via alteration in biochemical milieu
in ESRD patient is uniquely associated with an increased
amount of REM sleep in contrast to other therapeutic
attempts. This observation is consistent with the working
hypothesis that improvement with uremia clearance may be
associated with changes in the sleep architecture in ESRD
patients.
The notion that sleep apnea in ESRD is composed of an
even distribution of the obstructive, central, and mixed types,
implies that both upper airway occlusion and destabilization
of central ventilatory control play key roles in the pathogen-
esis of SAS in ESRD. Respiratory drive during sleep operates
under chemoreflex control. Hypocapnia resulting from
respiratory adaptation to chronic metabolic acidosis or to
the uremic state itself may be central to the development of
SAS in ESRD. As a result, it was proposed that ESRD patients
with SAS may have an altered chemoresponsiveness. Recently,
chemoreceptor activity was studied by Beecroft et al.36 In 49
ESRD patients, central and peripheral chemoresponsiveness
was measured under isoxic hypoxia and hyperoxia condi-
tions. These investigators found that basal ventilation was
similar in all subjects. However, patients with SAS were found
to have a higher ventilatory threshold and a higher sensitivity
to hypercapnia. These results suggest that sensitivities of both
central and peripheral chemoreceptors are increased in
patients with SAS and ESRD leading to destabilization of
respiratory control during sleep. Although alteration in
chemosensitivity during sleep may largely explain the
development of SAS in ESRD, other factors compromising
upper airway patency in ESRD may also contribute to sleep
apnea in uremic patients. These include extracellular fluid
volume overload leading to upper airway edema and reduced
upper airway muscle tone as a consequence of uremic
neuropathy.11,37
CLINICAL IMPLICATIONS OF SAS IN ESRD
Sleep apnea is characterized by repetitive cycles of apnea,
hypoxia, hypercapnia, and arousal.38,39 Subjects with upper
airway obstruction endure, in addition, sudden and pro-
found changes in cardiac loading conditions, secondary to
the abrupt generation of negative intra-thoracic pressure.
Acutely, each of these stimuli acts independently to trigger
central sympathetic outflow to the heart and periphery. The
gas exchange abnormalities, sleep fragmentation, and auto-
nomic activation have all been implicated as causes of the
substantial adverse health effects attributed to SAS.40 Because
sleep disturbance leads to daytime sleepiness and decreased
mental acuity, disturbed sleep may lead to decreased quality
of life,41 impaired cognitive ability,42 poor vocational
abilities, and increased illness intrusiveness.28,43
From a cardiovascular point of view, SAS is linked with
the development of hypertension, accelerated atherosclerosis,
heart failure, and ischemic strokes in the general popula-
tion.44–49 Given that cardiovascular mortality remains the
leading cause of death in ESRD, further characterization of
SAS in ESRD as a cardiovascular risk factor is of great clinical
interest.50
Normal non-REM sleep is characterized by reductions in
metabolic rate, sympathetic nervous system activity, heart
rate, cardiac output, and total peripheral resistance. Vagal
tone increases. This normal autonomic balance is disturbed
in patients with ESRD, especially in those with coexistent
SAS.51 Vagal modulation of heart rate is attenuated, and
sympathetic modulation predominates.
Increased cardiac and peripheral adrenergic drive may
help explain why sleep apnea and nocturnal hypoxemia have
been associated with left ventricular hypertrophy,52 hyper-
tension,53 and increased cardiovascular events in the chronic
heart disease (CHD) population.54
In addition to the neurohormonal hypothesis of SAS,
recent literature has linked nocturnal hypoxemia with
elevated oxidative stress and coronary calcification in CHD
patients. Jung et al.55 studied 26 CHD patients and
documented their overnight PSG, spiral computed tomo-
graphy-derived coronary artery calcification scores, and pre-
dialysis serum total antioxidant status. These investigators
demonstrated an association between AHI and coronary
calcification scores. Furthermore, the oxygen desaturation
index, a marker of nocturnal hypoxemia was negatively
correlated with total antioxidant status. The authors propose
that nocturnal hypoxemia followed by reoxygenation may
lead to free radical generation facilitating the process of
coronary calcification.
The awareness of SAS as a potent cardiovascular risk
factor in ESRD has generated new enthusiasm in examining
novel therapeutic strategies to modify sleep apnea in our
patient population. To date, conservative non-pharmaco-
logical treatments (e.g. weight loss and avoidance of
potentiating medications) have yielded limited success. Nasal
continuous positive airway pressure therapy remains a
mainstay of treatment of SAS in the non-ESRD population.
Continuous positive airway pressure involves a mask fitting
over the nose or mouth in which positive pressure is
administered to the airway keeping the upper airway patent
during sleep. In the general population, the treatment of sleep
apnea with continuous positive airway pressure improves
quality of life,56 vigilance, cognition, sexual performance, and
normalizes nocturnal blood pressure profile.57 In the ESRD
population, continuous positive airway pressure was used in
a small study of eight patients with some improvement in
nocturnal oxygenation, and five of six patients reporting
improved daytime alertness.31 Finally, given the contribution
of uremia in the pathogenesis of SAS in ESRD, attempts in
optimizing uremia control in the forms of nocturnal
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hemodialysis (NHD) and renal transplantation have shown
early clinical success.32,58,59 It is tempting to speculate that
similar to those with refractory hypertension, the treatment
of sleep apnea in the ESRD population would improve their
quality of life, augment rehabilitation, and perhaps impact on
the poor survival of our patients.
RESTLESS LEGS SYNDROME AND PERIODIC LEG MOVEMENTS
OF SLEEP
Restless legs syndrome (RLS) is a sensorimotor movement
disorder characterized by the irresistible need to move
associated with feelings of discomfort and parasthesias.
In contrast, periodic limb movement disorder (PLMD) are
sudden, repetitive, and highly stereotyped jerking leg
movements occurring during sleep. PLMD are identified
during sleep laboratory investigations. RLS is a diagnosis
based on history with standardized clinical criteria.60,61
(Table 1).
Although both primary and secondary forms of RLS and
PLMD exist, our discussion will be limited to secondary
forms of RLS and PLMD as a consequence of uremia and/or
concomitant iron deficiency.
PREVALENCE AND CLINICAL FEATURES OF RLS IN ESRD
In the general population, the prevalence of RLS has been
demonstrated to be between 5 and 15% with approximately
80% of patients with RLS also having PLMD.62,63 RLS have
been associated with poor quality of life, neuropsychiatric
symptoms, diminished cognition, and poor attention in both
dialysis patients and the general population.43,62–66 Defining
the prevalence of RLS in both the ESRD and general
population has been challenging as studies have been limited
by small sample size and differing diagnostic criteria used.
Similar to the unique clinical features of SAS in ESRD,
established non-uremic risk factors such as age and gender
are not often associated with the development of RLS in
uremia. In addition, pharmacological co-interventions may
also affect prevalence rates of RLS and PLMD. As a result, the
reported prevalence of this syndrome in uremia has ranged
between 6.6 and 83%.2,3,64,67–70
PATHOPHYSIOLOGY OF RLS/PLMD IN ESRD
The pathophysiology of RLS and PLMD in uremia remains
unknown however, several theories have been proposed.
Potential risk factors include anemia, iron deficiency, dialysis
vintage, calcium/phosphate imbalance, and peripheral and
central nervous system abnormalities.71
As iron is a cofactor of dopamine production in the
niagrostriatal areas of the brain, iron deficiency has long been
associated with the development of RLS in the general
population.72–75 In contrast, the role of anemia and iron
deficiency in the development of RLS in uremic patients have
been conflicting with only some studies indicating an inverse
association between iron deficiency and increasing risk of
developing RLS.67,69,76 Treatments with high-dose iron
dextran and normalization of hematocrit with recombinant
human erythropoietin have been demonstrated to improve
RLS/PLMD in ESRD patients.77,78 In the SLEEPO study,
normalization of the hematocrit was achieved with both
(recombinant human erythropoietin) and concomitant
increases in the dose of iron. It is therefore difficult to
attribute the observed beneficial effects solely to the use of
recombinant human erythropoietin.
Alterations in dopamine and opioid synthesis may also
play a role in the high prevalence of RLS and PLMD in
uremia; however, data are limited. Indirect evidence stems
from the notion that treatment with dopamine agonists,
dopamine precursors in ESRD patients may improve RLS
and PLMD symptoms.79–83
DRUG THERAPY OF RLS
Given that alterations of the dopaminergic pathways may
contribute to the development of RLS in ESRD, pharmaco-
logical treatment of RLS with Levodopa (L-DOPA) has been
studied and was shown to improve sleep and reduce
nocturnal limb movements in three prospective trials.79–81
Recently, treatment with pergolide, a dopamine agonist was
also examined in a double-blind placebo-controlled crossover
study in ESRD patients.83 In contrast to the use of L-DOPA,
pergolide resulted in decreased symptoms without objective
improvements in nocturnal limb movement or sleep
architecture. Limited beneficial data regarding the use of
other dopamine agonists have also been reported.84,85
(Table 2)
RLS/PLMD AND MORTALITY IN ESRD
In addition to diminished quality of life, RLS has been
associated with increased mortality in ESRD patients. Among
incident CHD and peritoneal dialysis patients from the
CHOICE cohort, severe symptoms of restless legs was
associated with shorter survival with a hazard ratio of 1.39
(95% confidence interval: 1.08–1.79).62 Other observational
data reported by Benz et al.86 demonstrated higher mortality
in 29 CHD patients affected by PLMD. Although the actual
Table 1 | The International RLS Study Group criteriaa
An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs.
The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying or sitting.
The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, for at least as long as the
activity continues.
The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night.
RLS, restless legs syndrome.
aAll four criteria are required for the diagnosis of restless legs syndrome.61
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mechanism underlying the heightened mortality in our
patient population with RLS and PLMD remains unknown,
potential contributors may include poor compliance with
hemodialysis and sympathetic overactivity secondary to sleep
fragmentation and recurrent arousals from sleep.
RENAL REPLACEMENT THERAPY AND SLEEP DISORDERS
IN ESRD
Conventional renal replacement does not correct sleep
disorders in ESRD
Conventional renal replacement strategies (CHD and perito-
neal dialysis) have not been shown to correct SAS associated
with ESRD.1,28,29 To date, the prevalence of sleep apnea is
similar in ESRD patients receiving either conventional
modalities.1,28,29 In addition, both CHD and peritoneal
dialysis have been postulated to alter sleep quality and have
potential effects on the mechanics of respiration. Several
reports have suggested that CHD is associated with the
release and production of sleep-inducing cytokines during
dialysis.19,20 Other authors have postulated that the mechan-
ical effects of peritoneal fluid on diaphragmatic excursion
may decrease total lung capacity, thereby contributing to
ventilatory instability.26 Similarly, consistent but limited data
also indicate that conventional renal replacement therapies
do not have any impact on RLS/PLMD in ESRD.3,71 Taken
together, it is reasonable to conclude that the present target of
uremia control remains ineffective for the treatment of EDS,
SAS, and RLS in ESRD.
OPTIMAL UREMIA CONTROL CORRECTS SLEEP DISORDERS
IN ESRD
Nocturnal hemodialysis
Given that uremia may be directly related to the development
of SAS in our patient population, it is reasonable to
hypothesize that intensifying uremia control will ameliorate
sleep disorders in ESRD.
Hanly and Pierratos32 showed that NHD was able to
correct SAS in ESRD. These investigators studied 14 CHD
patients before and after conversion to NHD with overnight
PSG. They found a significant reduction in the severity of
sleep apnea in all patients (AHI fell from 25725 to 878 per
hour; Po0.05). The effects of NHD were even more dramatic
in those patients with severe sleep apnea as AHI fell from
46719 to 9715 per hour; Po0.05. Similarly, nocturnal
hypoxemia was corrected with conversion to NHD. However,
total night time arousals remained elevated in NHD patients.
As nocturnal hypoxemia is related to sympathetic over-
activity in ESRD, it is reasonable to propose that correction
of SAS with NHD should accompany an improvement in the
autonomic modulation of heart rate during sleep. To this
aim, Chan et al.87 studied nine ESRD patients before and
after conversion to NHD and 10 control subjects. Power
spectral analysis of heart rate variability was applied to test
the hypothesis that NHD would lower sympathetic modula-
tion of heart rate during sleep. AHI, nocturnal hypoxemia,
and relative risk interval were significantly higher in ESRD
patients when receiving CHD than in healthy controls. After
conversion to NHD, there was a decrease in the frequency of
apnea and hypopnea, a reduction in the extent of hypoxemia,
and a fall in heart rate during sleep. Of specific interest, the
low frequency/high frequency ratio (a marker of sympathetic
to vagal balance) which was significantly higher in ESRD
patients receiving CHD than in control subjects (2.7770.82
vs. 0.7170.11; Po0.05) returned to control values
(0.7570.22, Po0.05 compared with CHD) after conversion
to NHD. The results from this study add to the body of
evidence that uremia-related sleep apnea with oxygen
desaturation is a potent stimulus to cardiac adrenergic drive,
and are consistent with the concept that the combination of
improved uremic clearance and lessened nocturnal hypox-
emia decreases cardiac sympathetic drive.
Although NHD has been shown to dramatically
correct SAS in ESRD patients, its therapeutic effect on
daytime sleepiness and PLMD is not as definitive. Hanly
et al.9 studied 24 unselected CHD patients. Of the study
cohort, 15 patients were subsequently trained on NHD.
Although there was a direct association between uremia
control (as indicated by plasma urea concentration) and
MSLT, this group of investigators did not find a significant
improvement in daytime sleepiness after conversion to
NHD in the short term. Further studies are required to
understand the influence of uremia control on daytime
sleepiness over time.
RENAL TRANSPLANTATION
Although there is limited published data regarding the effect
of renal transplantation on sleep disorders in ESRD, a
consistent trend was found indicating that optimizing uremia
control is associated with an improvement or correction of
uremia associated sleep disorders.
Observational cohort studies suggest that RLS improves
after renal transplantation.88 Additionally, there is a direct
association between allograft function and RLS severity.89
Finally, case report data have shown resolution of SAS after
renal transplantation.58,59
Table 2 | Stepwise therapeutic approach to RLS in dialysis
patients
1. History and physical examination to exclude and treat non-uremia
secondary causes of RLS.
2. Assess severity using standardized instruments: International Restless
Legs Syndrome Study Group severity scale.
3. If patient complains of mild to moderate RLS, consider the use of
non-pharmacological treatments.
Mental alerting activities.
Trial of caffeine, nicotine, and alcohol abstinence.
Eliminate aggravating medications (e.g., anti-depressants).
Consider change of dialysis time, dialysis modality or frequency.
4. Stepwise use of drug therapy.
Dopamine agonist (on dialysis days).
If unsuccessful – consider an alternate dopamine agonist.
If symptoms persist – consider L-DOPA.
If symptoms persist – consider adjunct therapy: gabapentin.
RLS, restless leg syndrome.
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CONCLUSION AND PERSPECTIVES
ESRD patients have a high prevalence of sleep disorders.
Recognition of the presence of sleep disorders in our patient
population is often complicated by the presence of co-
morbid illness and/or the uremic syndrome itself. Standard
sleep questionnaires have limited applicability in screening or
diagnosing ESRD patients with sleep disorders. Novel
screening tools or further refinement and validation of
existing diagnostic techniques are therefore needed.
Emerging evidence suggests that nocturnal hypoxemia and
the SAS are novel cardiovascular risk factors in ESRD.
Understanding of the increased morbidity and mortality of
sleep disorders in ESRD continues to evolve and requires
further characterization. Manipulation of uremia control and
its influence on sleep disorders will likely redefine our
therapeutic target for renal replacement therapy in the future.
(Figure 1).
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